- Home
- VFC vs IBRX Comparison
VFC vs IBRX Comparison
Compare VFC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VFC | IBRX |
|---|---|---|
| Founded | 1899 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 8.4B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VFC | IBRX |
|---|---|---|
| Price | $16.87 | $7.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $17.56 | $12.57 |
| AVG Volume (30 Days) | 5.6M | ★ 22.2M |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.72 | 38.71 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $10,488,556,000.00 | $113,288,000.00 |
| Revenue This Year | N/A | $88.59 |
| Revenue Next Year | $2.06 | $131.15 |
| P/E Ratio | $17.75 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $9.41 | $1.83 |
| 52 Week High | $21.92 | $12.43 |
Technical Indicators
Market Signals| Indicator | VFC | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 46.21 |
| Support Level | $13.83 | $5.89 |
| Resistance Level | $16.94 | $8.28 |
| Average True Range (ATR) | 0.66 | 0.94 |
| MACD | 0.15 | -0.21 |
| Stochastic Oscillator | 51.64 | 25.33 |
Price Performance
Historical ComparisonAbout VFC V.F. Corporation
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.